Robert W. Baird downgraded shares of Diplomat Pharmacy (NYSE:DPLO) from a neutral rating to an underperform rating in a research report report published on Wednesday morning, Marketbeat reports. Robert W. Baird currently has $10.00 target price on the stock, down from their previous target price of $22.00.
Other research analysts have also recently issued research reports about the stock. ValuEngine cut shares of Diplomat Pharmacy from a hold rating to a sell rating in a report on Wednesday, September 12th. Zacks Investment Research upgraded shares of Diplomat Pharmacy from a sell rating to a hold rating in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of $24.50.
Shares of Diplomat Pharmacy stock traded up $0.04 on Wednesday, hitting $16.09. The stock had a trading volume of 1,694,581 shares, compared to its average volume of 1,097,092. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.63 and a current ratio of 0.95. Diplomat Pharmacy has a one year low of $13.31 and a one year high of $28.74. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of 19.15 and a beta of 0.95.
In related news, Director Philip R. Hagerman sold 209,367 shares of the firm’s stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $19.07, for a total value of $3,992,628.69. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Philip R. Hagerman sold 57,500 shares of the firm’s stock in a transaction on Tuesday, September 11th. The stock was sold at an average price of $19.21, for a total value of $1,104,575.00. The disclosure for this sale can be found here. Company insiders own 24.70% of the company’s stock.
A number of hedge funds have recently made changes to their positions in DPLO. California Public Employees Retirement System purchased a new stake in Diplomat Pharmacy in the first quarter worth $547,000. UBS Group AG lifted its position in Diplomat Pharmacy by 186.4% during the first quarter. UBS Group AG now owns 8,491 shares of the company’s stock valued at $171,000 after buying an additional 5,526 shares during the period. Legal & General Group Plc lifted its position in Diplomat Pharmacy by 2.3% during the first quarter. Legal & General Group Plc now owns 100,097 shares of the company’s stock valued at $2,031,000 after buying an additional 2,264 shares during the period. Principal Financial Group Inc. lifted its position in Diplomat Pharmacy by 2.3% during the first quarter. Principal Financial Group Inc. now owns 369,023 shares of the company’s stock valued at $7,436,000 after buying an additional 8,258 shares during the period. Finally, Brown Advisory Inc. purchased a new position in Diplomat Pharmacy during the first quarter valued at $466,000. 82.05% of the stock is owned by institutional investors.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
See Also: Diversification Important in Investing
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.